Terapia inhibitorami kotransportera sodowo-glukozowego 2 – nie tylko dla diabetologów
Streszczenie
Recently, sodium-glucose co-transporter 2 inhibitors (SGLT2i) have made a major breakthrough in the treatment of type 2 diabetes mellitus (T2DM) and heart failure (HF). Dapagliflozin and empagliflozin are recommended to reduce risk of hospitalisation due to HF and cardiovascular (CV) death in heart failure with reduced ejection fraction (HFrEF). Moreover, dapagliflozin has also been shown to be an effective drug in the chronic kidney disease (CKD) patients' population, reducing the number of renal events and CV mortality. And sotagliflozin, which is also an inhibitor of sodium-glucose co-transporter 1 (SGLT1i), occured to be a beneficial therapy in patients with diabetes, hospitalised due to HF exacerbation. Subsequently, it also seems to be a drug that could be used in heart failure with preserved ejection fraction (HFpEF), however more studies are needed to support this conclusion.
Słowa kluczowe: inhibitory SGLT-2niewydolność sercaprzewlekła choroba nerek
Referencje
- Cosentino F, Grant PJ, Aboyans V, et al. ESC Scientific Document Group. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020; 41(2): 255–323.
- Bies E, Lelonek M. New approach to heart failure in diabetes mellitus. Folia Cardiol. 2019; 14(4): 411–417.
- Seferović PM, Petrie MC, Filippatos GS, et al. Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2018; 20(5): 853–872.
- Zinman B, Wanner C, Lachin JM, et al. EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015; 373(22): 2117–2128.
- McMurray JJV. EMPEROR-Reduced: confirming sodium-glucose co-transporter 2 inhibitors as an essential treatment for patients with heart failure with reduced ejection fraction. Eur J Heart Fail. 2020; 22(11): 1987–1990.
- McMurray JJV, Solomon SD, Inzucchi SE, et al. DAPA-HF Trial Committees and Investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019; 381(21): 1995–2008.
- Packer M, Butler J, Filippatos GS, et al. EMPEROR-Reduced Trial Committees and Investigators. Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial. Eur J Heart Fail. 2019; 21(10): 1270–1278.
- Verma S, McGuire D, Kosiborod M. Two tales: one story. Circulation. 2020; 142(23): 2201–2204.
- Packer M, Anker SD, Butler J, et al. EMPEROR-Reduced Trial Investigators. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020; 383(15): 1413–1424.
- Seferović PM, Fragasso G, Petrie M, et al. Heart Failure Association of the European Society of Cardiology update on sodium-glucose co-transporter 2 inhibitors in heart failure. Eur J Heart Fail. 2020; 22(11): 1984–1986.
- Bhatt DL, Szarek M, Steg PG, et al. SOLOIST-WHF Trial Investigators. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 2021; 384(2): 117–128.
- Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. DAPA-CKD Trial Committees and Investigators. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020; 383(15): 1436–1446.
- Butler J, Zannad F, Filippatos G, et al. Ten lessons from the EMPEROR-Reduced trial. Eur J Heart Fail. 2020; 22(11): 1991–1993.
